Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P2 alpelisib in PIK3CA-related overgrowth spectrum
NL-OMON54117Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS) (5 arms), sponsored by Novartis. Started Jan 2022; status: recruiting.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NL-OMON54117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54117.